Vaccine Contract Manufacturing Market (2nd Edition), 2019-2030

Vaccine Contract Manufacturing Market (2nd Edition), 2019-2030

The global vaccines market is anticipated to generate revenues worth USD 100 billion by 2025.
According to the WHO, the global vaccination rate is nearly 85%, demonstrating the high clinical demand for vaccines. In addition to meeting the growing demand for vaccines, the developers of these pharmacological interventions are also plagued by high costs of development and complex production protocols. Given that vaccine manufacturing requires highly regulated, state-of-the-art technologies, it has become increasingly difficult for stakeholders to establish in-house expertise for large-scale manufacturing of vaccines. As a result, vaccine developers have begun outsourcing their manufacturing operations to contract manufacturing organizations (CMOs). Specifically, small and mid-sized players in this sector tend to outsource a substantial proportion of clinical development and commercial-scale manufacturing processes to contract service providers. In addition, even big pharma players, with established in-house capabilities, are gradually entering into long-term business relationships with CMOs in order to optimize resource utilization and manage costs.

It is worth highlighting that the contemporary contract services market for vaccines is highly fragmented. Having said that, numerous stakeholders are actively striving to expand their respective service portfolios through substantial acquisition activity. As a result, these CMOs have developed the capabilities to offer end-to-end services, ranging from vaccine development (including preliminary R&D, preclinical studies and clinical trials), to regulatory filings, and commercial scale production. In future, we expect the demand for core competencies to continue to drive sponsor companies to rely on contract service providers for various aspects of product development and manufacturing. Amidst tough competition, the availability of cutting-edge tools and technologies has emerged as a differentiating factor and is likely to grant a competitive advantage to certain CMOs over other players in the industry.

SCOPE OF THE REPORT

The “Vaccine Contract Manufacturing Market (2nd Edition), 2019 – 2030” report features an extensive study on contract service providers engaged in the development and manufacturing of vaccines. The study features in-depth analyses, highlighting the capabilities of various vaccine CMOs. Amongst other elements, the report includes:

A detailed review of the contract manufacturing landscape for vaccines, featuring a comprehensive list of active CMOs and analysis based on a number of parameters, such as year of establishment, company size, geographical location, number of vaccine manufacturing facilities, types of services offered (cell / virus banking, analytical development / testing, formulation, process development, fill / finish and regulatory filings), scale of operation (preclinical, clinical and commercial), type of expression systems used (mammalian, microbial and others) and type(s) of vaccines manufactured.

A region-wise, company competitiveness analysis, highlighting prominent vaccine contract manufacturers based on supplier strength (considering the experience of the contract manufacturer), and service strength (which takes into account the count of service offerings, number of expression systems used and scale of operation).

Elaborate profiles of the key players based in North America, Europe and Asia-Pacific that have a diverse range of capabilities for the development, manufacturing and packaging of vaccines. Each profile includes an overview of the company, its financial performance (if available), information on service portfolio, vaccine manufacturing facilities, and details on partnerships, recent developments (expansions), and awards and accolades received, as well as an informed future outlook.

An analysis of the recent collaborations (signed since 2013) focused on the contract manufacturing of vaccines, based on various parameters, such as year of agreement, type of agreement, scale of operation, types of services mentioned in the deal, types of vaccines manufactured, types of therapeutic area and location of facility where the project is to be executed.

A detailed analysis of the expansions undertaken (since 2013) by various service providers within vaccine contract manufacturing industry, based on a number of parameters, including year of expansion, type of expansion (capacity expansion, capability expansion and new facility), geographical location of facility, scale of operation, types of services involved, expansion details (in terms of new area added to existing facilities, if available) and most active players (in terms of number of instances).

An informed estimate of the annual demand for vaccines (in mL), taking into account the 20 top selling vaccines, based on various parameters, such as target patient population, dosing frequency and dose strength.

A detailed capacity analysis, taking into consideration the manufacturing capacities of various stakeholders (small-sized, mid-sized, large and very large CMOs) in the market, based on data gathered via secondary and primary research. It also provides the distribution of global vaccine manufacturing capacity by company size (small-sized, mid-sized, large and very large), and geography (North America, Europe and Asia-Pacific) and scale of operation (preclinical / clinical and commercial).

A discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall industry.

A discussion on the potential market drivers, such as the growing vaccines pipeline, increasing outsourcing of vaccine operations and opportunities in Asia-Pacific region, which are likely to present in the coming years.

One of the key objectives of the report was to estimate the future size of the market. Based on the parameters, such as growth of the overall vaccine market, cost of goods sold, and direct manufacturing costs, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and mid to long term, for the period, 2019-2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] commonly outsourced vaccine-related operations (cell / virus banking, analytical development / testing, formulation, process development, fill / finish and regulatory filings) [B] types of expression systems (mammalian, microbial and others), [C] size of contract service provider company (small-sized, mid-sized and large / very large), [D] scale of operation (preclinical, clinical and commercial) and [E] key geographical regions (North America (US, Canada), Europe (UK, France, Germany, Italy and Spain), Asia (China and India) and rest of the world. To account for the uncertainties associated with the manufacturing of vaccines and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:
Menzo Havenga, CEO, Batavia Biosciences and Claire Otjes, Marketing Manager, Batavia Biosciences
David C Cunningham, Director Corporate Development, Goodwin Biotechnology
Ingrid Cromann, Director - Vaccine Development, Statens Serum Institut
Kevin Daley, Director Pharmaceuticals, Novasep Synthesis
Oliver Schub, Senior Business Development Manager, ProBioGen
Sebastian Schuck, Head of Business Development, Wacker Biotech

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINES
Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the likely evolution of the vaccine contract manufacturing market in the mid to long term.

Chapter 3 provides a general introduction to vaccines. The chapter also includes an overview of the various expression systems used in the development and manufacturing of vaccines. It also features a brief overview of contract manufacturing and a detailed discussion on the need for outsourcing within the vaccines industry. The chapter includes a list of commonly outsourced vaccine manufacturing services and concludes with a discussion on the challenges that are currently associated within this market.

Chapter 4 provides a comprehensive overview of the global vaccine contract manufacturing landscape. It includes information related to over 90 CMOs that are currently active in this domain. In addition, it features an in-depth analysis of the market, based on a number of parameters, such as the year of establishment, company size, geographical location, number of vaccine manufacturing facilities, types of services offered (cell / virus banking, analytical development / testing, formulation, process development, fill / finish and regulatory filings), scale of operation (preclinical, clinical and commercial), type of expression systems used (mammalian, microbial and others) and type(s) of vaccines manufactured.

Chapter 5 features a comprehensive company competitiveness analysis of vaccine contract manufacturers based in North America, Europe and Asia-Pacific, that we came across during our research. The analysis compares companies within each geography on the basis of supplier strength (considering the experience of contract manufacturer) and service strength (which takes into account the count of service offerings, number of expression systems used, and scale of operation).

Chapter 6 provides detailed profiles of some of the key players that are active in the vaccine contract manufacturing market in North America. Each profile presents a brief overview of the company, financial information (if available), its contract service offerings highlighting the capabilities of vaccine product facilities, recent developments and an informed future outlook.

Chapter 7 provides detailed profiles of some of the key players that are active in the vaccine contract manufacturing market in Europe. Each profile presents a brief overview of the company, financial information (if available), its contract service offerings highlighting the capabilities of vaccine product facilities, recent developments and an informed future outlook.

Chapter 8 provides detailed profiles of some of the key players that are active in the vaccine contract manufacturing market in Asia-Pacific. Each profile presents a brief overview of the company, financial information (if available), its contract service offerings highlighting the capabilities of vaccine product facilities, recent developments and an informed future outlook.

Chapter 9 features an elaborate analysis and discussion on the collaborations and partnerships that have been inked amongst players, since 2013. It includes brief descriptions of the various partnership models (including acquisition, distribution agreement, licensing agreements, manufacturing, product development / commercialization, product development and manufacturing, process development and manufacturing, process development, R&D agreements, service alliance and others) that have been adopted by stakeholders in this domain. It also includes analysis based on year of agreement, type of agreement, scale of operation, types of services mentioned in the deal, types of vaccines manufactured, types of therapeutic area and location of facility where the project is to be executed. Further, the chapter features a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 10 presents detailed analysis on the expansions that have taken place in the vaccine manufacturing industry, since 2013. It includes information on expansions for increasing existing capabilities, as well as setting-up of new facilities by service provider entities engaged in this domain. The expansion instances that we came across were analyzed based on various parameters, including year of expansion, type of expansion (capacity expansion, capability expansion and new facility), geographical location of the facility, scale of operation (as mentioned in the expansion terms), types of services involved, expansion details (in terms of new area added to the existing facilities, if available) and also highlights the most active players (in terms of number of instances) in the domain.

Chapter 11 features an analysis of the global / regional capacity of contract manufacturers that are engaged in the manufacturing of vaccine products. The analysis takes into consideration the individual development and manufacturing capacities of various stakeholders (small-sized, mid-sized, large and very large CMOs) in the market, using data from both secondary and primary research. The study examines the distribution of global vaccine manufacturing capacity by size of the company (small-sized, mid-sized, large / very large), region of operation (North America Europe Asia-Pacific and, rest of the world and scale of operation (preclinical / clinical, commercial).

Chapter 12 features an informed view on the demand for vaccines (both clinical and commercially available) in the market, offering an informed opinion on the required scale of supply (in terms of vaccine manufacturing services). For the purpose of estimating the current clinical demand, we considered the active clinical studies of different types of vaccines that have been registered since 2010. The data was analyzed on the basis of various parameters, such as types of vaccines, types of indications and geography. Further, in order to estimate the commercial demand, we considered the annual volume of vaccine doses sold, based on a various parameter, such as types of vaccines and geography.

Chapter 13 presents an insightful market forecast analysis, highlighting the likely growth of the vaccine contract manufacturing market till the year 2030. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] types of expression systems (mammalian, microbial and others) [B] size of the company (small-sized, mid-sized and large / very large), [C] scale of operation (preclinical, clinical and commercial) and [D] key geographical regions (North America (US, Canada), Europe (UK, France, Germany, Italy and Spain), Asia (China, India and Japan) and rest of the world.

Chapter 14 provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of biopharmaceuticals manufacturing market, under a comprehensive SWOT framework.

Chapter 15 highlights the potential growth drivers for contract vaccine manufacturers. It highlights the various opportunities associated with the growing vaccine pipeline, increase in outsourcing of vaccine manufacturing operations, adoption of innovative technologies and opportunities in Asia-Pacific region, which are likely to have a notable influence on the future of the vaccine contract manufacturing market.

Chapter 16 features the transcripts of interviews conducted with representatives from renowned organizations that are engaged in the vaccine contract manufacturing domain. We spoke to Menzo Havenga (CEO, Batavia Biosciences) and Claire Otjes (Marketing Manager, Batavia Biosciences), David C Cunningham (Director Corporate Development, Goodwin Biotechnology), Ingrid Cromann (Director - Vaccine Development, Statens Serum Institut), Kevin Daley (Director Pharmaceuticals, Novasep Synthesis), Oliver Schub (Senior Business Development Manager, ProBioGen), Raquel Fortunato (CEO, GenIbet Biopharmaceuticals), Sebastian Schuck (Head of Business Development, Wacker Biotech), Stephen Taylor (Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies).
Chapter 17 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 18 is an appendix that provides the list of companies and organizations mentioned in the report.

LIST OF COMPANIES

1. 3P Biopharmaceuticals
2. Abenza
3. Acambis
4. Accugenix
5. Actavis
6. Adimmune
7. Advanced BioScience Laboratories (ABL)
8. Advaxis
9. Aeras
10. AGC Biologics
11. AJ Biologics
12. Ajinomoto Bio-Pharma Services
13. Albany Molecular Research
14. Alexion Pharmaceuticals
15. Algonomics
16. Altaris Capital Partners
17. Amatsigroup
18. AmbioPharm
19. AMRI
20. AnaSpec
21. Aptuit
22. Arabio
23. Association for Assessment and Accreditation of Laboratory Animal Care
24. Aventis Pasteur
25. Avid Bioservices
26. Bachem
27. Batavia Biosciences
28. Battelle
29. Bavarian Nordic
30. Baxter BioPharma Solutions
31. Baylor Institute for Immunology Research
32. BD Biosciences
33. Benchmark Vaccines
34. Bharat Biotech
35. Bharat Serums and Vaccine
36. Bill & Melinda Gates Foundation
37. Bilthoven Biologicals
38. Binex
39. Bio Elpida
40. BioCell
41. Biocon
42. BioConnections
43. BioConvergence
44. Bio-Ess Laboratories
45. Biofabri
46. Biofarma
47. Bioline
48. Biological E
49. BioMARC
50. Biomay
51. Biomed
52. Biomedical Advanced Research and Development Authority
53. BioMotiv
54. BiondVax Pharmaceuticals
55. BioReliance (Subsidiary of Sigma Aldrich)
56. BioTechLogic
57. BioTechnique
58. Biotechnology and Biological Sciences Research Council
59. Biotechnology Development for Industry
60. Biovac
61. Biovest International
62. Birgi Mefar Group
63. Boehringer Ingelheim BioXcellence
64. Boston Children’s Hospital
65. Brammer Bio
66. BravoVax
67. Bristol-Myers Squibb
68. Bryllan
69. Burrard Pharmaceuticals
70. Cadila
71. CALIXAR
72. Canadian Animal Health Institute
73. Canadian Council on Animal Care
74. Cangene
75. CARBOGEN AMCIS
76. Catalent
77. Celsis International
78. Centers for Disease Control and Prevention (CDC)
79. Century Pharmaceuticals
80. CEPI (the Coalition for Epidemic Preparedness Innovations)
81. CEPiA
82. Cetus
83. CEVEC Pharmaceuticals
84. Changchun BCHT Biotechnology
85. Charles River Biopharmaceutical Services (BPS)
86. Charles River Laboratories
87. Chimera Biotec
88. China Agricultural University
89. China National Biotec Group
90. Chinese Center for Disease Control and Prevention
91. Chinese University of Hong Kong
92. Chiron Behring Vaccines (acquired by Bharat Biotech)
93. Cobra Biologics
94. Cook Pharmica
95. Crucell Sweden
96. Cytovance Biologics
97. Daiichi Sankyo
98. Dalton Pharma Services
99. Deltamune
100. Department of Defense
101. Disposable Lab
102. Dr. Reddy's Laboratories
103. Dyadic International
104. EGYVAC
105. EirGenix
106. Emergent Biosolutions
107. Engineering and Physical Sciences Research Council
108. ERC Belgium
109. Eubiologics
110. Eurogentec
111. European Medicines Agency
112. European veterinary pharmaceutical company
113. ExpreS2ion Biotech Holding
114. Exxell BIO
115. Federation of Indian Chambers of Commerce and Industry
116. Florida Biologix
117. French National Agency for Research on AIDS and Viral Hepatitis
118. Friedrich-Loeffler-Institut
119. FUJIFILM Diosynth Biotechnologies
120. Gallant Custom Laboratories
121. Gamma Vaccines
122. GAVI
123. GC CelL
124. Genentech
125. GENEWIZ
126. GenIbet Biopharmaceuticals
127. Genzyme Polyclonals
128. GlaxoSmithKline
129. GNH India Pharmaceuticals
130. Goodwin Biotechnology
131. Grand River Aseptic Manufacturing
132. Greenpak Biotech
133. Grifols
134. GSAL
135. GTP Technology
136. Guangxi Veterinary Research Institute
137. Guangzhou Air force Hospital
138. Haffkine Institute
139. HALIX
140. Harbin Veterinary Research Institute
141. Health Biotech
142. Hennepin Healthcare Research Institute
143. HLL Biotech
144. Hong Kong Institute of Biotechnology
145. IDRI
146. IDT Biologika
147. ImevaX
148. Immune Design
149. Immune Targeting Systems (acquired by Vaxin)
150. Immunex
151. Immunobiological Technology Institute (Bio-Manguinhos)
152. ImmunoSite Technologies
153. ImVisioN Therapeutics
154. Index Ventures
155. Indian Council of Medical Research
156. Indian Immunologicals
157. Infectious Disease Research Institute
158. Innovate UK
159. INSERM-ANRS
160. Intas Biopharmaceuticals
161. Integrity Bio
162. International AIDS Vaccine Initiative (IAVI)
163. International Medica Foundation
164. International Society for Pharmaceutical Engineering
165. Interros
166. Intervacc
167. Inviragen (acquired by Takeda)
168. Irvine Pharmaceutical Services (acquired by Nitto Avecia Pharma Services)
169. Israel Institute for Biological Research
170. JHP Pharmaceuticals
171. JSR
172. Jubilant HollisterStier
173. KABS Pharmaceutical Services
174. Kalon Biotherapeutics
175. Kaneka
176. KBI Biopharma
177. Kemwell Biopharma
178. LigoCyte Pharmaceuticals
179. Lonza
180. LuinaBio
181. Magellan BioScience Group
182. MassBiologics
183. Medicago
184. Medicines and Healthcare products Regulatory Agency
185. Merck
186. Meridian Life Science
187. Minhai Biotechnology
188. Minneapolis Medical Research Foundation (MMRF)
189. Mitsubishi Gas Chemical
190. Mitsubishi Tanabe Pharma
191. Moderna Therapeutics
192. Mymetics
193. Najít Technologies
194. National Avian Influenza Reference Laboratory
195. National Cancer Institute
196. National Heart, Lung, and Blood Institute
197. National Institute of Allergy and Infectious Diseases (NIAID)
198. NewLink Genetics
199. NIAID
200. Nitto Avecia Pharma Services
201. Norwegian Institute of Public Health
202. Nouscom
203. Novartis
204. Novasep
205. Novavax
206. NPO Petrovax Pharm
207. OctoPlus
208. Okairos
209. Oncotest
210. Organization for Economic Cooperation and Development
211. OSO BioPharmaceuticals Manufacturing
212. Ottawa Hospital Research Institute (OHRI)
213. Pacific GMP
214. Panacea Biotec
215. Panacea Pharmaceuticals
216. Paragon Bioservices
217. PATH
218. Patheon
219. PaxVax
220. Pfenex
221. Pfizer
222. Pfizer CentreOne
223. PharmaPak
224. PharmaSynth
225. Pierre Fabre
226. Piramal Pharma Solutions
227. Polymun Scientific
228. Porton Biopharma
229. Premas Biotech
230. Prime European Therapeuticals
231. ProBioGen
232. Profectus BioSciences
233. Prometic Life Sciences
234. Protagen
235. PX’Therapeutics
236. QuiaPEG Pharmaceuticals
237. RAFAGEN
238. Recipharm
239. Reliance Life Sciences
240. Richter-Helm
241. RIEMSER Pharma
242. Riemser Pharma
243. Rommelag CMO
244. SAFC
245. Sanofi Active Ingredient Solutions
246. Sanofi Pasteur
247. Sartorius Stedim Biotech
248. Serum Institute of India
249. Serum Institute of India and its wholly owned subsidiary Bilthovan Biologicals
250. Shandong Zhaoxin Bio-tech
251. Shanghai Laboratory Animal Center
252. ShangPharma Innovation
253. Shasun Pharmaceuticals
254. Shenzhen Kangtai Biological Products
255. SialoCarb
256. Sichuan Agricultural University
257. Sigma-Aldrich
258. SK Chemicals
259. Soligenix
260. South China Agricultural University
261. State Secretariat for Education, Research and Innovation
262. Statens Serum Institut
263. Stellar Biotechnologies
264. Sumagen
265. Swissfillon
266. SynCo Bio Partners
267. Syngene (a subsidiary of Biocon)
268. Synthelis
269. Takeda Pharmaceuticals
270. Temasek Life Sciences Ventures
271. The Friedrich-Loeffler-Institut, the Federal Research Institute for Animal Health
272. The Hong Kong Jockey Club Charities Trust
273. The Israel Institute for Biological Research
274. Thermo Fisher Scientific
275. Thomas Jefferson University
276. Tianjin CanSino Biotechnology
277. TJU
278. Transgene
279. Unitech Pharma Group
280. United States Army Medical Research Institute of Infectious Diseases
281. Univercells
282. University of Copenhagen
283. University of Maryland
284. University of Oxford
285. University of Pennsylvania
286. Upperton Pharma Solutions
287. USAMRIID
288. Vaccibody
289. VACSERA
290. Vacsera and its subsidiary Egyvac
291. Valerius Biopharma
292. Valneva
293. Valneva’s Clinical Manufacturing Operations in Nantes
294. Vaxin
295. Vetter Pharma
296. VGXI
297. Vibalogics
298. Vivalis
299. VRI
300. Vybion
301. Wacker Biotech
302. Waisman Biomanufacturing
303. Walter Reed Army Institute of Research
304. Wellcome Trust
305. WIL Research
306. Wockhardt
307. World Trade Organization
308. WuXi AppTec
309. WuXi Biologics
310. Wuxi Fortune Pharmaceutical
311. WuXi Griffin
312. Zoetis